A
Adlai Nortye Ltd
NASDAQ:ANL
Adlai Nortye Ltd
NASDAQ:ANL
Price:
9.55
USD
-7.1%
Market Cap:
$615m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
A
|
Adlai Nortye Ltd
NASDAQ:ANL
|
KY |
|
F
|
Forte Minerals Corp
F:2OA
|
CA |
|
M
|
Myriad Genetics Inc
F:MYD
|
US |
|
A
|
Arcos Dorados Holdings Inc
F:AD8
|
UY |
|
Dian Swastatika Sentosa Tbk PT
IDX:DSSA
|
ID |
|
First Hartford Corp
OTC:FHRT
|
US |
|
L
|
Lundin Gold Inc
F:F1YN
|
CA |
|
A
|
Asahi Group Holdings Ltd
XMUN:ABW
|
JP |
|
A
|
Alarm.com Holdings Inc
F:3RL
|
US |
|
Eagle High Plantations Tbk PT
F:7B7
|
ID |
|
T
|
T-Mobile US Inc
F:TM5
|
US |
Intrinsic Value
Not Available for ANL
There is not enough data to reliably calculate the intrinsic value for Adlai Nortye Ltd.
Do our valuations actually work? See backtest results .
Alternatives to ANL
Fundamental Analysis
What Adlai Nortye Does
Adlai Nortye Ltd. is a clinical-stage biotechnology company that develops cancer medicines, with a focus on drugs that target tumor growth signals and help the immune system attack cancer. Its work is centered on discovering, testing, and advancing experimental therapies through clinical trials rather than selling approved medicines at scale.
- Headquarters
- Cayman Islands KY
- Employees
- 109
- IPO date
- Sep 29, 2023
Financials
Efficiency
Earnings Waterfall
Adlai Nortye Ltd
Adlai Nortye Ltd
